Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-ranging randomized trial of tildacerfont in adults with classic congenital adrenal hyperplasia
2019-004764-22Phase 2Active
- Sponsor
- Spruce Biosciences, Inc.
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in 21-hydroxylase deficiency (21-OHD) comparing Tildacerfont dose-ranging with Placebo (2 arms). Primary endpoint: Percent change from baseline in androstenedione (A4) at Week 18. Started Jul 2020; status: active.
02
Drugs
tildacerfont
03
Conditions
21-hydroxylase deficiency (21-OHD)
Beyond the preview
Go deeper on 2019-004764-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004764-22.